What is Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) share price return in the past 10 years?

Biofil Chemicals & Pharmaceuticals Ltd share price has appreciated 17.4% annually (CAGR) over the past ten years.

What is the share price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) on 17-Apr-2026 16:59:59 at 16:59 is 34.40.

What is the P/E ratio of Biofil Chemicals & Pharmaceuticals?

The latest standalone P/E ratio of Biofil Chemicals & Pharmaceuticals as of 17-Apr-2026 is 20.20.

What is the P/B ratio of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)?

The latest standalone P/B ratio of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) as of 17-Apr-2026 is 2.62.

What is the 52-week high and low of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)?

The 52-week high of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) is Rs. 56.36 and the 52-week low is Rs. 25.60.

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)
Brand: Biofil Chemicals & Pharmaceuticals

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 524396 NSE: BIOFILCHEM | Trading | Small Cap

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)

BSE: 524396 NSE: BIOFILCHEM

Key Metrics

Market Cap

₹56 Cr.

P/E Ratio

20.20

Price to Book (P/B)

2.62

Price to Sales (P/S)

1.92

EV/EBITDA

15.75

Return on Capital Employed (ROCE)

4.08%

Current Price

₹34.4

Return on Equity (ROE)

3.02%

Return on Assets (ROA)

1.14%

Operating Profit Margin

2.5%

Net Profit Margin

1.67%

Gross Profit Margin

3.3%

Book Value per Share

₹13.1

Sales Growth (YoY)

-16.58%

Sales Growth (3 Years)

14.28%

Operating Profit Growth (1 Year)

3.66%

Operating Profit Growth (3 Years)

-13.86%

Net Profit Growth (1 Year)

-21.13%

52-Week Low / High

₹26 / 56

Net Profit Growth (3 Years)

-7.22%

Dividend Yield

0.00%

Promoter Holding

46.79%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Biofil Chemicals & Pharmaceuticals Ltd?

Biofil Chemicals & Pharmaceuticals Ltd revenue growth is -16.6% for FY-2025 , which is below its 5 year CAGR of 2.4% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Biofil Chemicals & Pharmaceuticals Ltd?

Promoters hold 46.79% of the Biofil Chemicals & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Biofil Chemicals & Pharmaceuticals Ltd vs industry peers?

Biofil Chemicals & Pharmaceuticals Ltd revenue CAGR is 2.38% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Biofil Chemicals & Pharmaceuticals Ltd belong to?

Biofil Chemicals & Pharmaceuticals Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.

Q.1 Stock return of Biofil Chemicals & Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 17.5% based on the current price.

DeciZen - make an informed investing decision on Biofil Chem & Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Biofil Chemicals & Pharmaceuticals stock performance

Key Ratios

Is Biofil Chemicals & Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Biofil Chemicals & Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Biofil Chemicals & Pharmaceuticals Ltd is a below average quality company.

2. Is Biofil Chemicals & Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Biofil Chemicals & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Biofil Chemicals & Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Biofil Chemicals & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	14%	21.9%	5.1%	5.1%	10.1%	12.2%	6.2%	4.8%	5%	4.1%	-
Value Creation Index ⓘ	0	0.6	-0.6	-0.6	-0.3	-0.1	-0.6	-0.7	-0.7	-0.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	13.2	13.5	12.4	23.1	29.7	35.8	22.4	30	40	33.4	29
Sales YoY Gr.	-	2.1%	-8.1%	87.1%	28.4%	20.4%	-37.4%	34.2%	33.3%	-16.6%	-
Adj EPS ⓘ	0.5	1.1	0.3	0.3	0.7	0.8	0.4	0.3	0.4	0.3	1.7
YoY Gr.	-	129.2%	-73.6%	3.5%	146.7%	2.7%	-43.4%	-20.9%	29.4%	-22.7%	-
BVPS (₹) ⓘ	4.4	7.8	8.1	8.4	9.2	9.9	10.4	10.6	11.2	11.5	13.1
Adj Net Profit ⓘ	0.8	1.8	0.5	0.5	1.2	1.2	0.7	0.6	0.7	0.6	3
Cash Flow from Ops. ⓘ	0.1	0.7	0.5	1.3	0.9	1.1	-0.2	-0.1	2.4	-1.9	-
Debt/CF from Ops. ⓘ	10	2	3.4	1.3	1.3	0.4	-2.1	-4.7	0.2	-0.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.9%	2.4%	14.3%	-16.6%
Adj EPS ⓘ	-3.8%	-14.4%	-7.5%	-22.7%
BVPSⓘ	11.3%	4.8%	3.7%	3.1%
Share Price	17.4%	-12.4%	-8%	-26.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	8.1	15.2	3.6	3.6	8.5	8	4.2	3.3	4	3	13.8
Op. Profit Mgn % ⓘ	6.6	19.5	7.6	4.4	6.1	4.5	6	3.9	2	2.5	1.1
Net Profit Mgn % ⓘ	5.9	13.3	3.8	2.1	4.1	3.5	3.1	1.9	1.8	1.7	9.5
Debt to Equity ⓘ	0.2	0.1	0.1	0.1	0.1	0	0	0	0	0	-
Working Cap Days ⓘ	271	371	397	223	282	281	262	192	267	429	195
Cash Conv. Cycle ⓘ	43	31	139	68	51	65	74	101	76	102	53

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 13.80%

Sales growth is growing at healthy rate in last 3 years 14.28%

Sales growth is good in last 4 quarters at 74.75%

Net Profit has been subdued in last 3 years -7.53%

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	1.7	-
TTM Sales (₹ Cr.)	29.2	-
BVPS (₹) ⓘ	13.1	-
Reserves (₹ Cr.) ⓘ	5	-
P/BV ⓘ	2.62	-
PE ⓘ	20.20	-

From the Market
52 Week Low / High (₹)	25.60 / 56.36
All Time Low / High (₹)	0.30 / 352.45
Market Cap (₹ Cr.)	56
Equity (₹ Cr.)	16.3
Face Value (₹)	10
Industry PE ⓘ	25.8

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Biofil Chem & Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	13.17	13.45	12.36	23.13	29.69	35.75	22.38	30.04	40.04	33.40
Operating Expenses ⓘ +	12.30	10.83	11.42	22.11	27.87	34.15	21.05	28.87	39.22	32.55
Manufacturing Costs	0.85	0.91	0.48	0.58	1.04	0.59	0.45	0.49	0.69	0.56
Material Costs	10.52	8.51	9.77	19.99	25.31	32.43	19.46	27.42	37.51	30.85
Employee Cost	0.48	0.53	0.73	0.89	0.86	0.75	0.79	0.45	0.50	0.61
Other Costs ⓘ	0.44	0.88	0.45	0.64	0.65	0.38	0.35	0.51	0.53	0.54
Operating Profit ⓘ	0.87	2.62	0.94	1.02	1.82	1.60	1.33	1.17	0.82	0.85
Operating Profit Margin (%)	6.6%	19.5%	7.6%	4.4%	6.1%	4.5%	6.0%	3.9%	2.0%	2.5%
Other Income ⓘ +	0.53	0.14	0.10	0.10	0.17	0.80	0.15	0.10	0.49	0.31
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.15	0.16	0.15	0.16	0.12	0.07	0.04	0.04	0.04	0.04
Depreciation ⓘ	0.26	0.28	0.30	0.37	0.41	0.41	0.43	0.43	0.40	0.38
Profit Before Tax ⓘ	0.98	2.31	0.59	0.60	1.46	1.92	1.01	0.79	0.87	0.74
Tax ⓘ	0.20	0.52	0.12	0.12	0.26	0.68	0.32	0.23	0.16	0.18
Profit After Tax	0.78	1.79	0.47	0.48	1.21	1.24	0.70	0.56	0.71	0.56
PAT Margin (%)	5.9%	13.3%	3.8%	2.1%	4.1%	3.5%	3.1%	1.9%	1.8%	1.7%
Adjusted EPS (₹)	0.5	1.1	0.3	0.3	0.7	0.8	0.4	0.3	0.4	0.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	10.91	12.70	13.17	13.65	14.88	16.13	16.84	17.30	18.20	18.78
Share Capital ⓘ	16.27	16.27	16.27	16.27	16.27	16.27	16.27	16.27	16.27	16.27
Reserves ⓘ	-5.37	-3.58	-3.11	-2.62	-1.39	-0.14	0.56	1.03	1.93	2.51
Debt +	1.37	1.43	1.56	1.64	1.19	0.43	0.46	0.52	0.44	0.47
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	1.37	1.43	1.56	1.64	1.19	0.43	0.46	0.52	0.44	0.47
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	11.59	7.10	9.14	8.58	25.92	15.85	0.60	12.65	27.55	30.99
Others Liabilities ⓘ	0.26	0.62	0.29	0.34	0.37	0.83	0.83	0.93	0.89	0.72
Total Liabilities ⓘ	24.13	21.84	24.15	24.21	42.36	33.24	18.73	31.41	47.08	50.96
Fixed Assets
Net Fixed Assets ⓘ +	8.98	9.16	9.25	10.29	10.09	9.78	9.42	9	8.62	8.34
Gross Block	11.04	9.45	9.83	11.24	11.45	11.55	11.62	11.63	11.65	11.75
Accumulated Depreciation	2.06	0.29	0.58	0.95	1.36	1.77	2.20	2.63	3.03	3.41
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0.10	0.17	1.02	1.19	1.69	4.34	1.29	1.21	2.55	3.34
Trade Receivables	13.98	11.46	12.98	12.03	29.71	17.22	7.17	20.50	33.03	38.32
Cash Equivalents	0.18	0.31	0.37	0.14	0.26	0.44	0.14	0.04	2.28	0.26
Others Assets ⓘ	0.89	0.74	0.53	0.57	0.62	1.46	0.70	0.65	0.60	0.70
Total Assets ⓘ	24.13	21.84	24.15	24.21	42.36	33.24	18.73	31.41	47.08	50.96

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.14	0.71	0.46	1.26	0.89	1.11	-0.22	-0.11	2.39	-1.92
PBT ⓘ	0.98	2.31	0.59	0.60	1.46	1.92	1.01	0.79	0.87	0.74
Adjustment ⓘ	0.42	0.45	0.45	0.53	0.56	0.48	0.48	0.38	0.63	0.44
Changes in Working Capital ⓘ	-0.96	-1.84	-0.07	0.25	-0.87	-0.62	-1.4	-1.05	1.05	-2.92
Tax Paid ⓘ	-0.15	-0.20	-0.50	-0.11	-0.25	-0.68	-0.32	-0.23	-0.16	-0.18
Cash Flow From Investing Activity ⓘ +	-0.19	-0.48	-0.38	-1.41	-0.21	-0.10	-0.07	-0.01	-0.02	-0.10
Capex	-0.19	-0.48	-0.38	-1.41	-0.21	-0.10	-0.07	-0.01	-0.02	-0.10
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	0.10	-0.11	-0.02	-0.08	-0.57	-0.83	-0.01	0.02	-0.12	-0
Net Proceeds from Shares ⓘ	1.71	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	-0.16	-0.15	-0.16	-0.12	-0.07	-0.04	-0.04	-0.04	-0.04
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1.61	0.06	0.13	0.08	-0.45	-0.76	0.03	0.06	-0.08	0.03
Net Cash Flow ⓘ	0.05	0.13	0.06	-0.24	0.12	0.18	-0.30	-0.11	2.25	-2.03

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	13.28	18.09	3.64	3.6	8.46	8.01	4.24	3.28	4	3.02
ROCE (%)	14.04	21.86	5.13	5.06	10.12	12.18	6.23	4.76	4.97	4.08
Asset Turnover Ratio	0.7	0.59	0.54	0.96	0.89	0.95	0.86	1.2	1.02	0.68
PAT to CFO Conversion(x)	0.18	0.4	0.98	2.63	0.74	0.9	-0.31	-0.2	3.37	-3.43
Working Capital Days
Receivable Days	244	345	361	197	257	240	199	168	244	390
Inventory Days	4	4	18	17	18	31	46	15	17	32
Payable Days	238	401	303	162	249	235	154	88	196	346

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Biofil Chemicals & Pharmaceuticals Ltd FAQs

The current trading price of Biofil Chem & Pharma on 17-Apr-2026 16:59 is ₹34.40.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Biofil Chem & Pharma stood at ₹55.98 Cr

The latest P/E ratio of Biofil Chem & Pharma as of 16-Apr-2026 is 20.20.

The latest P/B ratio of Biofil Chem & Pharma as of 16-Apr-2026 is 2.62.

The 52-week high of Biofil Chem & Pharma is ₹56.36 and the 52-week low is ₹25.60.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Biofil Chem & Pharma is ₹29.18 ( Cr.) .

About Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals established in 1985, is part of Cyano Group of Industries. The company is into manufacturing of drugs in area of anti-bacterial, analgesics/antipyretics, anti-malarial, anti-psychotics, anti asthmatic/bronchodilators, diuretics, tranquilizer/hypnotics, anti inflammatory, analgesic/antipyretics, anti inflammatory steroids and eye/ear drops

Its plant is located at Plot No. 8, Sector-IV Kheda Industrial Estate, Pithampur, Dhar District, Madhya Pradesh. The facility has received GMP certificate from Licensing Authority, Food & Drugs Administration, Department of Health and Government of Madhya Pradesh, India.

The manufacturing unit exports around 30 to 40% of their formulation directly or through merchant export to countries in own or neutral labels.

The shares of companies are listed on Bombay Stock Exchange.

Company exports its products to countries namely Kenya, Uganda, Tanzania, Nigeria, U.A.E, Rwanda, Monrovia, Republic of Yemen and Mauritius.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Biofil Chem & Pharma Share Price